Cabozantinib and Pembrolizumab in Metastatic Pancreas

Joseph Kim

Status and phase: Completed; Phase 2

Conditions: Pancreatic Cancer

Treatments: Drug: Cabozantinib; Drug: Pembrolizumab

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05052723

MCC-21-GI-117

Details and patient eligibility

About

This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.

Enrollment: 21 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of pancreatic ductal adenocarcinoma
• Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies
• Patients must have adequate organ function

Exclusion criteria

• Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation
• Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention
• Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation
• Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy
• Clinically significant cardiovascular disease
• Uncontrolled hypertension
• Inability to swallow tablets

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

21 participants in 1 patient group

Cabozantinib and pembrolizumab

Experimental group

Treatment:

Drug: Pembrolizumab

Drug: Cabozantinib